In focus
VS Pharmtech's VS-101 Turns Radiation Into a Sharper Weapon Against Cancer
VS Pharmtech is developing VS-101, a repositioned radiosensitizer that weakens cancer cells' DNA repair and aims to boost existing treatments at roughly one-fifth the original dose. Early Korean trial data and FDA-cleared Phase 2 plans have put the Seoul startup on a global licensing path.
Read the story